Overview

A Study of LAM-002A for the Prevention of Progression of COVID-19

Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
Phase:
Phase 2
Details
Lead Sponsor:
AI Therapeutics, Inc.
Collaborator:
Yale University